PRGO 8-K 2026-11-04
PERRIGO Co plc (PRGO) 8-K dated 2026-11-04 — accession 0001585364-26-000160.
PERRIGO Co plc (PRGO) is a drug manufacturers - specialty & generic company listed on US.
PRGO to acquire platform ($162M)
This 8-K covers: Results of operations (Item 2.02), Exhibits (Item 9.01). SEC EDGAR holds the official filing and its exhibits.
Latest reported PRGO revenue for 2025-12-31 was $4.25B. Net income was -$1.43B. Revenue was down 2.8% from 2024-12-31 to 2025-12-31. PRGO currently screens at market cap $1.48B.
Not investment advice. The PRGO SEC hub lists recent forms. The stock page is the research view.
- Diluted EPS
- $0.09
- Guidance
- full-year 2026 outlook to reflect divestiture, more measured retailer inventory positioning, and continued softness in Europe
- Deal
- $162M
Why it matters
- full-year 2026 outlook to reflect divestiture, more measured retailer inventory positioning, and continued softness in Europe
- Transaction value about $162M
- Our Three-S plan is delivering continued progress in the areas of the business within our control,…